Lipoprotein(a) is associated with atherosclerotic cardiovascular disease (ASCVD) in individuals with non‐diabetes, prediabetes, or diabetes independent of C-reactive protein (CRP)
Authors' conclusion
Elevated Lp(a) levels were associated with a higher risk of ASCVD across different glucose metabolism statuses, particularly among individuals with NGR and prediabetes, independent of baseline CRP levels.
Study context
- Population
- UK Biobank participants without prevalent ASCVD: 253,746 with normal glucose regulation (NGR), 38,020 with prediabetes, 15,503 with diabetes; mean age 57 years (Q1-Q3: 50–63), 55.3% female29,521 ASCVD events
- Participants
- 307,269 participants
- Exposure
- Top 10% vs bottom 33% of Lp, by glucose metabolism status
- Outcome
- Time to ASCVD events
- Follow-up
- Median 13.2 years
Methodological detailsprospective, UK Biobank
- Prospective
- UK Biobank
Main finding
As reported in the abstract
ASCVD
Top 10% Lp(a) vs Bottom 33% Lp(a)Hazard ratio (95% CI)
NGR
1.28(1.22–1.34)
Prediabetes
1.23(1.12–1.35)
Diabetes
1.16(1.02–1.31)
Observational data: associations, not effects.
Further findings
Interaction with CRP (<2/≥2 mg/L) across glucose metabolism groups
- No significant interactions after stratification by CRP
- P for interaction > 0.05
Original publication
Lipoprotein(a) is associated with ASCVD in individuals with non‐diabetes, prediabetes, or diabetes independent of CRP. Diabetes Obes Metab. Published 21 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →